reason report
lean forward toledo rais pt
bottom line discuss investor sinc glpg event
novemb shown us persist sens confus within
investor commun transform glpg view
summer deal creat lot move part difficult
track given econom wrinkl agreement
movement around stock took time effort consolid
inform one place rais pt per adr
base high convict manag filgotinib
toledo
deal leav valu ceil open glpg exchang
cash gain opt-in right late stage clinic
asset aris glpg pipelin opt-in decis glpg
receiv up-front mileston payment split futur expens
asset receiv tier royalti commerci
sale outsid europ filgotinib
uniqu mileston commerci arrang place meanwhil
glpg retain european right lean commerci
foundat establish filgotinib support futur product
launch idiopath pulmonari fibrosi ipf first
potenti drug approv project launch glpg
full european econom agreement leav glpg view well
posit grow european biotech powerhous
convinc ad toledo valuat due high
opinion root overwhelm convict manag
emphasi strength scienc toledo program
ad toledo valuat glpg similar filgotinib
profil pipeline-in-a-drug toledo capabl posit multipl
drug emerg program develop across rang
inflammatori diseas current valu toledo program
per adr use valuat filgotinib comp
valu adjust account differ project launch year
toledo first indic ptr probabl technic
regulatori success anticip full reveal toledo ident
coincid initi proof-of-concept poc readout
filgotinib nda file close today glpg partner
announc submit nda fda prioriti
review filgotinib treat rheumatoid arthriti ra file
prioriti review voucher put filgotinib track regulatori decis
 launch expect soon approv file also
trigger mileston payment glpg fda join
ema europ pmda japan third regulatori agenc
take filgotinib review
sotp wacc-calcul
discount rate termin growth
rate discount cash flow valu
asset dcf valu
adjust asset specif probabl
year price history/av daili volume mil glpg
compani inform svb leerink llc research
rev mm ep dilut non-gaap
pleas refer page import disclosur price chart analyst certif
assumpt drive pt rais pt increas per adr
driven two assumpt make ahead import
catalyst first ad per adr toledo base
compar analysi valuat filgotinib second
rais probabl approv filgotinib ra ad
per adr base efficaci safeti profil shown
clinic increas partial off-set dilut across
valuat caus gild warrant exercis novemb
encourag timeli nda file filgotinib
expect use prioriti review voucher addit toledo
remain signific addit valuat
addit valu upsid catalyst rich beyond toledo
reveal poc readout filgotinib anticip approv ra
addit catalyst give opportun valuat
growth posit top-line phase result osteoarthr
could trigger per adr mileston
addit per adr avail estim chang ptr
posit top-line result phase ulcer coliti
uc trial filgotinib would increas pt addit per adr
consid development mileston may trigger
manag guid mileston
distribut across filgotinib program final would
demand greater attent within valuat achiev
posit top-line phase result idiopath pulmonari fibrosi ipf
filgotinib superior safeti profil versu jaki make potenti best-in-class jaki
opportun compet anti-tnf agent rheumatoid arthriti ra
inflammatori bowel diseas ibd believ glpg potenti best-in-car drug
potenti becom standard care ipf treatment
limit effect treatment idiopath pulmonari fibrosi ipf carri
blockbust potenti project market launch toledo rebal
inflammatori anti-inflammatori cytokin hit yet unrev target
howev base inform avail believ toledo potenti disrupt
inflammatori medicin market final view gain approv treat
osteoarthr oa highli unlik given histori clinic effort ignor
massiv opportun gain regulatori approv
research develop collabor provid signific up-front cash
promis futur develop expect glpg proprietari discoveri platform
continu produc uniqu profil drug keep door open partnership
deal leav open sky valuat gain glpg
summer announc collabor chang valu trajectori
glpg infus cash gave glpg financi resourc
expand activ plan earli stage expand oligonucleotid discoveri
give abil target protein code genom rather
current small molecul platform enabl hit glpg select
acquisit seek expand discoveri capabl target
compani synergist fit glpg cultur focu high qualiti scienc
beyond boon effort collabor agreement also updat filgotinib
agreement specif glpg commerci role potenti approv launch
filgotinib enabl glpg systemat build commerci presenc europ
collabor agreement also give glpg opportun realiz earlier econom
clinic stage asset exchang cash receiv opt-in right asset
glpg pipelin reach late stage clinic develop opt-in mileston
glpg receiv vari per-asset basi trigger consid
qualifi trial name phase trial posit data posit drug
phase pivot trial addit opt-in payment assum
expens asset move forward owe tier royalti glpg
commerci sale outsid europ term exclud filgotinib glpg
alreadi exist agreement place glpg partner
servier ex-u region outsid two drug glpg retain full commerci
right europ asset opt
filgotinib origin filgotinib agreement updat collabor
 cost updat split rather split
commerci respons europ also specif defin
ra glpg lead commerci effort franc itali spain lead
commerci effort germani ibd respons revers
glpg lead effort germani lead franc
itali spain glpg lead commerci effort diseas group
belgium netherland luxembourg benelux econom split
countri regardless indic commerci lead
lead commerci effort remaind europ rest
world glpg receiv tier royalti origin
mileston alloc regulatory/r commerci
thu far glgp receiv portion neither glpg
disclos trigger size remain mileston
program although assum signific portion develop mileston
come upon filgotinib approv ra achiev posit result
phase trial uc expect
alreadi opt program opt-in fee
recogn glpg glpg receiv mileston
approv ipf glpg elig receiv
tier royalti ex-european sale importantli opt-in agreement
give right europ glpg instead retain full
commerci right econom owe
on-going phase roccella trial osteoarthr serv
qualifi trial elig licens commerci right
glpg elig receiv mileston payment upon
achiev primari endpoint roccella addit trigger
trial met certain secondari endpoint like womac ontario
mcmaster univers osteoarthr index score glpg also elig
receiv commerci mileston tier royalti
sale glpg prior agreement servier remain place glpg elig
receiv mileston high singl digit royalti commerci sale
outsid program outsid filgotinib glpg
retain full european right due partnership agreement servier
toledo everyth els opt-in option molecul
develop glpg next year asset opts-in
glpg receiv elig receiv tier royalti
futur ex-european sale glpg retain full commerci right europ
toledo molecul consid separ asset
opt-in fee
warrant agreement rais gild ownership glpg gave
two block warrant first block exercis novemb
origin agreement price per adr per share increas gild
ownership second block exercis time next
year price equal trail stock price rais gild
ownership
commerci path europ
glpg either lead share commerci activ major european market franc
germani itali spain belgium luxembourg netherland give glpg
opportun systemat build commerci infrastructur key
countri ahead european launch drug commerci strategi differ
drug indic
filgotinib separ sale forc requir market ra versu ibd make
sens consid lack locat specialti overlap rheumatologist
gastroenterologist glpg given guidanc number filgotinib sale
rep expect hire countri verbal commit match
number sale rep op sale group rinvoq upadacitinib pre-
commerci effort well underway glpg fill key strategi posit
experienc hand big pharma glpg expect netherland germani
first european countri approv filgotinib ra
commerci strategi differ ipf ipf less preval
diseas ipf patient europ vs ra ibd patient specialist
treatment option tend central major hospit european
countri ipf specialist major hospit glpg expect hire
sale rep across europ reli infrastructur establish
support filgotinib big plu benelux infrastructur european countri
establish separ time depend project approv date
regulatori path europ multistep process
drug approv europ oper two-tier system drug first requir
gain regulatori approv ema compani must seek approv negoti
price countri countri basi countri approv
reimburs system caus avail vari throughout europ
expect glpg target larger higher reimburs market first step
commerci footprint across europ also expect approv time
acceler rel approv time filgotinib given dire natur ipf
fda ema partial agre pivot natur isabela
phase trial ident double-blind placebo
control trial investig two dose qd top
standard care nintedanib pirfenidon therapeut intervent trial
measur differ rate declin forc vital capac fvc week versu
placebo studi power show signific differ primari
endpoint exclud safeti reason patient abl chang assign
treatment regimen random chang background
medic glpg expect patient evenli distribut across background therapi arm
suffici number patient enrol abl measur efficaci subgroup
despit expect patient switch background medic
manag indic partial overlap agreement fda european
medicin agenc ema constitut suffici robust trial full regulatori
approv ipf agenc agreement twin isabela trial
suffici regulatori approv part combin regimen
either nintedanib perfenidon pend posit data addit fda believ
monotherapi arm trial suffici robust allow approv glpg
monotherapi howev ema less posit robust monotherapi
arm may requir follow-up placebo control compar trial
overwhelm monotherapi efficaci data isabela
glpg announc updat time scope plan futil analysi
isabela trial day futil analysi conduct
patient origin complet week treatment push project
time futil analysi back howev analysi larger sampl
patient provid increas confid trial futil analysi
recommend trial continu expect trial fulli nearli fulli enrol
time futil analysi set pace project top-line readout
 market launch project drug gain regulatori approv
give credit toledo
ascrib per adr toledo use filgotinib comp assum toledo
revenu cash flow mirror project revenu cash flow filgotinib
exclud mileston includ premium sg sinc toledo
sale synergi filgotinib main countri also market part
europ glpg lack filgotinib sale forc present valu unadjust revenu
cash flow filgotinib adjust ptr toledo place
project launch year toledo adjust cash flow
discount present valu use discount rate appli sum
part valuat also includ opt-in fee three differ toledo molecul
project occur also adjust
ad toledo valuat glpg base convict scientif
team bolster level resourc compani commit program
glpg current commit personnel toledo project includ
discoveri scientist chemist intent move rapidli
possibl establish preclin scienc build legal protect prior reveal
ident toledo target expect
 day novemb glpg reveal toledo compris member
make toledo target uniqu inhibit reduc
product inflammatori cytokin also increas product anti-inflammatori
cytokin combinatori mechan act re-establish balanc within immun
system therebi suppress inflammatori episod except
select inhibit increas product anti-inflammatori
glpg advanc toledo molecul clinic goal develop
multipl toledo molecul leverag target differ combin
target differ combin produc differ safety/efficaci profil may
provid distinct advantag particular indic
gener toledo molecul pan-tol inhibitor enter small phase
proof concept poc trial ibd expect readout follow-up discuss
manag state demonstr best result ever seen
across preclin ibd model gener toledo molecul
select inhibit spare multipl phase proof concept
poc trial plan expect begin read
select inhibitor begin phase pk/safeti studi
toledo molecul thu far demonstr efficaci ibd
presum due lack influenc express instead glpg initi
develop molecul ra glpg intend reveal gener toledo
molecul
glpg envis develop toledo molecul take place three wave
first wave includ initi phase dose studi follow small poc trial wave
includ dose-find larger poc studi expect trigger opt-in decis
wave investig toledo indic outsid inflamm glpg
current work better understand scienc surround molecul
implic outsid inflamm
pt determin use probabl weight scenario analysi individu
scenario valu determin sum part valuat appli wacc
calcul discount rate termin growth rate revenu cash flow
project revenu asset adjust independ twice
probabl regulatori approv asset specif commerci profil
commerci probabl distribut determin base revenu weight
distribut independ commerci scenario project drug candid
filgotinib toledo cash reserv compris major valuat
galapago held cash cash equival end
risk valuat includ follow
product risk one clinic trial filgotinib may fail meet
primari endpoint necessit deeper decis continu develop
particular indic addit safeti issu occur within one trial filgotinib
may read neg across entir filgotinib franchis
collabor risk glpg pipelin lead asset filgotinib subject risk relat
glpg collabor agreement gilead collabor agreement give glpg
limit abil address situat issu surround success drug
regulatori risk fda previous indic belief drug combin
like futur ipf treatment mind glpg pursu pivot trial investig
combin standard care believ creat safer path
approv nonetheless open door potenti competitor pursu path
approv monotherapi significantli disrupt expect market competit
financ risk glpg current revenu produc product market though
well capit near term neg outcom asset franchis may
significantli impact abil rais fund futur
econom commerci respons differ drug region
split
rest world
asset
rest europ
rest europ
tier royalti outsid
benelux
europ indic
remain
alreadi opt
owe upon
fee plu addit
specif secondari endpoint
met phase trial
commerci mileston
per asset basi
toledo molecul
higher convict filgotinib toledo rais pt
increas pt glpg per share per share base addit per share ad
toledo per share ad filgotinib assumpt get approv ra partial off-set per
share dilut follow warrant exercis novermb
valuat toledo use valuat filgotinib compar program unadjust cash flow filgotinib
re-adjust ptr toledo place discount present valu yield valuat per
glpg pipelin valu primarili deriv asset filgotinib per share per share toledo
pipelin asset per share cash per share oper per share reconcil pt
brand
type event
event trial detail
date known
up/down
expect
proof concept trial gener toledo
initi multipl poc studi
proof concept top-line result
top-line result proof concept trial
launch
launch
futil analysi phase isabela trial
svb leerink llc equiti research compani file
good sold
research develop expens
gener administr expens
sale market expens
profit loss oper
fair valu re-measur share subscript agreement
total incom expens
loss oper tax
good sold
research develop expens
gener administr expens
sale market expens
profit loss oper
fair valu re-measur share subscript agreement
total incom expens
loss oper tax
growth profit ratio
cash equival
trade receiv
properti plant equip
trade payabl
total liabil stockhold equiti deficit
outstand share end period thousand
work capit thousand
cash equival market secur
cash equival
trade receiv
properti plant equip
trade payabl
total liabil stockhold equiti deficit
outstand share end period thousand
work capit thousand
cash equival market secur
flow oper activ
reconcili net loss net cash
adjust non-cash transact
adjust item disclos separ oper cash flow
adjust item disclos invest financ cash flow
increas decreas oper asset liabil
chang work capit defer incom
decreas defer incom
oper activ work capit cash flow
net interest tax- oper cash flow
net cash use oper activ
flow invest activ
purchas properti plant equip
purchas expenditur intang fix asset
proce dispos properti plant equip
decreas restrict cash
proce sale financi asset held fair valu profit loss
acquisit available-for-sal financi asset
net cash provid use invest activ
flow financ activ
repay oblig financ leas debt
proce capit share premium increas gross amount
issu cost paid relat capit share premium increas
proce capit share premium increas exercis warrant
net cash provid financ activ
effect exchang rate differ cash cash equival
net increas decreas cash cash equival
 cash equiv begin period
 cash equival end period
burn cash use opex
annual cash burn annual
year cash remain
month cash remain
flow oper activ
reconcili net loss net cash
adjust non-cash transact
adjust item disclos separ oper cash flow
adjust item disclos invest financ cash flow
increas decreas oper asset liabil
chang work capit defer incom
decreas defer incom
oper activ work capit cash flow
net interest tax- oper cash flow
net cash use oper activ
flow invest activ
purchas properti plant equip
purchas expenditur intang fix asset
proce dispos properti plant equip
decreas restrict cash
proce sale financi asset held fair valu profit loss
acquisit available-for-sal financi asset
net cash provid use invest activ
flow financ activ
repay oblig financ leas debt
proce capit share premium increas gross amount
issu cost paid relat capit share premium increas
proce capit share premium increas exercis warrant
net cash provid financ activ
effect exchang rate differ cash cash equival
net increas decreas cash cash equival
 cash equiv begin period
 cash equival end period
burn cash use opex
annual cash burn annual
year cash remain
month cash remain
part total
